Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14520631 | 0.87 | USP2 (0.59) | SMN1; SMN2TP53DRD2DRD4USP2 | |
| SCHEMBL23407902 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2TP53DRD2DRD4USP2 | |
| SCHEMBL21107025 | 0.85 | MEN1 (0.45) | SMN1; SMN2TP53DRD2DRD4USP2 | |
| SCHEMBL12017899 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2TP53DRD2DRD4USP2 | |
| SCHEMBL21107592 | 0.84 | MEN1 (0.47) | SMN1; SMN2TP53DRD2DRD4USP2 | |
| SCHEMBL22856287 | 0.84 | MEN1 (0.47) | SMN1; SMN2TP53DRD2DRD4USP2 | |
| SCHEMBL18028204 | 0.83 | RAD52 (0.55) | SMN1; SMN2TP53DRD2DRD4USP2 | |
| SCHEMBL13115892 | 0.83 | RAD52 (0.55) | SMN1; SMN2TP53DRD2DRD4USP2 | |
| SCHEMBL18908763 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2TP53DRD2DRD4USP2 | |
| SCHEMBL22054371 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53DRD2USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2017091673-A2 | BIVALENT BROMODOMAIN INHIBTORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221826-A1 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | SMN1; SMN2 3934/4885TP53 609/4885DRD2 2213/4885 |
| US-20220119416-A9 | BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BET1, BRD2 | SMN1; SMN2 3934/4885TP53 609/4885DRD2 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.